SCHEMBL26613480

SCHEMBL26613480

Cc1ccc2nc(-c3ccc4c(c3)CCC(=O)N4)ccc2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.58
▸ NPC1 O15118 1/20 0.58
▸ MMP12 P39900 1/20 0.58
▸ RAB9A P51151 1/20 0.58
▸ MEN1 O00255 1/20 0.56
▸ KMT2A Q03164 1/20 0.56
▸ ALDH1A1 P00352 2/20 0.53
▸ HTT P42858 2/20 0.53
▸ POLB P06746 1/20 0.53
▸ SMN1; SMN2 Q16637 1/20 0.53
▸ CYP11B1 P15538 3/20 0.46
▸ CYP11B2 P19099 3/20 0.46
▸ PDE3B Q13370 3/20 0.46
▸ PDE3A Q14432 3/20 0.46
▸ CYP1A2 P05177 3/20 0.46
▸ CYP2C9 P11712 2/20 0.46
▸ TBXAS1 P24557 1/20 0.46
▸ KIF11 P52732 1/20 0.46
▸ CYP2D6 P10635 1/20 0.45
▸ CYP2B6 P20813 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29746163 1.00 MAPT (0.58) MAPTNPC1MMP12RAB9AMEN1
SCHEMBL26613471 0.85 MAPT (0.53) MAPTNPC1MMP12RAB9AMEN1
SCHEMBL29746115 0.85 MAPT (0.53) MAPTNPC1MMP12RAB9AMEN1
SCHEMBL26613494 0.84 MAPT (0.56) MAPTNPC1MMP12RAB9AMEN1
SCHEMBL26613552 0.79 MAPT (0.54) MAPTNPC1MMP12RAB9AMEN1
SCHEMBL26089507 0.78 KIF11 (0.50) MAPTNPC1MMP12RAB9AALDH1A1
SCHEMBL14865934 0.77 KIF11 (0.68) MAPTNPC1MMP12RAB9AMEN1
SCHEMBL29199433 0.77 PKM (0.58) MAPTNPC1MMP12RAB9AMEN1
SCHEMBL433753 0.77 PKM (0.58) MAPTNPC1MMP12RAB9AMEN1
SCHEMBL29746473 0.74 AHR (0.58) MAPTALDH1A1HTTPOLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260083723-A1 THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS TORAY INDUSTRIES, INC. (JP) 2026-03-26 — — US disclosed
US-12570639-B2 Tetrahydroquinoline derivative and medicinal use thereof TORAY INDUSTRIES, INC. (JP) 2026-03-10 — — US disclosed
EP-4545079-A1 THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS Toray Industries, Inc. (JP) 2025-04-30 — — EP disclosed
US-20240116903-A1 TETRAHYDROQUINOLINE DERIVATIVE AND MEDICINAL USE THEREOF TORAY INDUSTRIES, INC. (JP) 2024-04-11 — — US disclosed
WO-2023249105-A1 THERAPEUTIC AGENT OR PREVENTIVE AGENT FOR DRUG-INDUCED MYOCARDIAL DISORDERS 東レ株式会社 2023-12-28 — — WO disclosed
WO-2023249107-A1 THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR PERIPHERAL NERVE DISORDER 東レ株式会社 2023-12-28 — — WO disclosed
WO-2023249106-A1 THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS 東レ株式会社 2023-12-28 — — WO disclosed
EP-4269392-A1 TETRAHYDROQUINOLINE DERIVATIVE AND MEDICINAL USE THEREOF Toray Industries, Inc. (JP) 2023-11-01 — — EP disclosed
EP-4269392-A1 TETRAHYDROQUINOLINE DERIVATIVE AND MEDICINAL USE THEREOF Toray Industries, Inc. (JP) 2023-11-01 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240116903-A1 TETRAHYDROQUINOLINE DERIVATIVE AND MEDICINAL USE THEREOF AIFM2, TXNRD2, NFE2L2 MAPT 1384/4885NPC1 579/4885MMP12 1208/4885
US-20260083723-A1 THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS AIFM2, GPX1, SOD1 MAPT 2282/4885NPC1 532/4885MMP12 2080/4885
US-12570639-B2 Tetrahydroquinoline derivative and medicinal use thereof AIFM2, GPX1, GPX4 MAPT 4049/4885NPC1 134/4885MMP12 988/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback